Kamada KMDA
NASDAQ KMDA
$8.21 -0.08 (-0.97%)
As of: Sep 9, 2026 · 3:35 PM EDT

Kamada (KMDA) Non Operating Interest Expenses (2012 - 2026)

Kamada's (KMDA) quarterly Non Operating Interest Expenses came in at -$371000.0 in Q2 2026, down 2750.0% on a YoY basis from $14000.0 in Q2 2025, and down 97.34% quarter-over-quarter from -$188000.0 in Q1 2026.

Analysis

Kamada (KMDA) Non Operating Interest Expenses (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Non Operating Interest Expenses for 15 consecutive years, with -$371000.0 the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Non Operating Interest Expenses fell 2750.0% year-over-year to -$371000.0; the trailing twelve-month figure through Jun 2026 stood at -$1.0 million (down 94.57% YoY), and the FY2025 full-year result was -$864000.0, down 30.91% from the prior year.
  • Non Operating Interest Expenses eased to -$371000.0 in Q2 2026 per KMDA's latest filing, from -$188000.0 in the prior quarter.
  • Across five years, Non Operating Interest Expenses topped out at $2.1 million in Q1 2023 and bottomed at -$2.2 million in Q4 2023.
  • Historically, Non Operating Interest Expenses has averaged $533555.6 across 5 years, with a median of $370000.0 in 2023.
  • The sharpest annual moves came in 2022 and 2026: Non Operating Interest Expenses surged 4823.81% in 2022, then sank 2750.0% in 2026.
  • Over 5 years, Non Operating Interest Expenses stood at $1.1 million in 2022, then sank by 309.7% to -$2.2 million in 2023, then soared by 91.59% to -$189000.0 in 2024, then plunged by 37.04% to -$259000.0 in 2025, then tumbled by 43.24% to -$371000.0 in 2026.
  • According to Business Quant data, Non Operating Interest Expenses over the past three periods registered -$371000.0, -$188000.0, and -$259000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Amgen 211.77 Bn 197.79 Bn 7.24 Bn 673.00 Mn
2 Gilead Sciences 181.13 Bn 177.95 Bn 6.22 Bn 247.00 Mn
3 Vertex Pharmaceuticals 132.24 Bn 124.39 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.89 Bn 74.89 Bn 3.93 Bn 11.00 Mn
5 Argenx Se 61.56 Bn 56.38 Bn 1.37 Bn -1.00 Mn
6 Moderna 54.38 Bn 49.24 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 34.44 Bn 31.13 Bn 992.69 Mn 82.05 Mn
8 Biogen 31.17 Bn 29.89 Bn 1.96 Bn -
9 Roivant Sciences 30.12 Bn 30.12 Bn 1.16 Mn -
10 Kamada 473.28 Mn 403.14 Mn 22.47 Mn -371,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -371,000.00
Mar 31, 2026 -188,000.00
Dec 31, 2025 -259,000.00
Sep 30, 2025 -221,000.00
Jun 30, 2025 14,000.00
Mar 31, 2025 -192,000.00
Dec 31, 2024 -189,000.00
Sep 30, 2024 -167,000.00
Jun 30, 2024 1.15 Mn
Mar 31, 2024 1.60 Mn
Dec 31, 2023 -2.25 Mn
Sep 30, 2023 1.07 Mn
Jun 30, 2023 726,000.00
Mar 31, 2023 2.09 Mn
Dec 31, 2022 1.07 Mn
Sep 30, 2022 2.07 Mn
Jun 30, 2022 1.62 Mn
Mar 31, 2022 2.03 Mn
Dec 31, 2021 1.36 Mn
Sep 30, 2021 42,000.00